Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 221

1.

Benefits and risks of bisphosphonate therapy for osteoporosis.

Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM, Recker RR, Shane E, Shoback D, Potts JT.

J Clin Endocrinol Metab. 2012 Jul;97(7):2272-82. doi: 10.1210/jc.2012-1027. Epub 2012 Apr 20. Review.

PMID:
22523337
2.

Long-term use of bisphosphonates in osteoporosis.

Watts NB, Diab DL.

J Clin Endocrinol Metab. 2010 Apr;95(4):1555-65. doi: 10.1210/jc.2009-1947. Epub 2010 Feb 19. Review.

PMID:
20173017
3.
4.

Bisphosphonate adverse effects, lessons from large databases.

Abrahamsen B.

Curr Opin Rheumatol. 2010 Jul;22(4):404-9. doi: 10.1097/BOR.0b013e32833ad677. Review.

PMID:
20473174
5.

[Bisphosphonate-associated osteonecrosis of the jaw in rheumatology: a systematic review].

Capsoni F.

Reumatismo. 2008 Jan-Mar;60(1):6-13. Review. Italian.

6.

Osteonecrosis of the jaw: balancing the benefits and risks of oral bisphosphonate treatment for osteoporosis.

Jeffcoat M, Watts NB.

Gen Dent. 2008 Jan-Feb;56(1):96-102; quiz 103-4, 111-2. Review.

PMID:
18254568
7.

Osteonecrosis of the jaw in older osteoporosis patients treated with intravenous bisphosphonates.

Baillargeon J, Kuo YF, Lin YL, Wilkinson GS, Goodwin JS.

Ann Pharmacother. 2011 Oct;45(10):1199-206. doi: 10.1345/aph.1Q239. Epub 2011 Sep 27.

8.

Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday.

McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, Hanley DA, Kendler DL, Yuen CK, Lewiecki EM.

Am J Med. 2013 Jan;126(1):13-20. doi: 10.1016/j.amjmed.2012.06.023. Epub 2012 Nov 20. Review.

PMID:
23177553
9.

Osteonecrosis of the jaw after oral bisphosphonate for osteoporosis.

Tong CK, Ho ST, Wong SL.

Hong Kong Med J. 2010 Apr;16(2):145-8.

10.

Risk of osteonecrosis of the jaw in cancer patients taking bisphosphonates.

Gebara SN, Moubayed H.

Am J Health Syst Pharm. 2009 Sep 1;66(17):1541-7. doi: 10.2146/ajhp080251. Review.

PMID:
19710437
11.

Safety of long-term bisphosphonate therapy for the management of osteoporosis.

Lewiecki EM.

Drugs. 2011 Apr 16;71(6):791-814. doi: 10.2165/11585470-000000000-00000. Review.

PMID:
21504254
12.

Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients.

Hoff AO, Toth B, Hu M, Hortobagyi GN, Gagel RF.

Ann N Y Acad Sci. 2011 Feb;1218:47-54. doi: 10.1111/j.1749-6632.2010.05771.x. Epub 2010 Sep 28. Review.

PMID:
20946574
13.

Insight into bisphosphonate-associated osteomyelitis of the jaw: pathophysiology, mechanisms and clinical management.

Wimalawansa SJ.

Expert Opin Drug Saf. 2008 Jul;7(4):491-512. doi: 10.1517/14740338.7.4.491 . Review.

PMID:
18613812
14.

Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome.

Yarom N, Yahalom R, Shoshani Y, Hamed W, Regev E, Elad S.

Osteoporos Int. 2007 Oct;18(10):1363-70. Epub 2007 Jun 28.

PMID:
17598065
15.

Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw.

Khan AA, Sándor GK, Dore E, Morrison AD, Alsahli M, Amin F, Peters E, Hanley DA, Chaudry SR, Dempster DW, Glorieux FH, Neville AJ, Talwar RM, Clokie CM, Al Mardini M, Paul T, Khosla S, Josse RG, Sutherland S, Lam DK, Carmichael RP, Blanas N, Kendler D, Petak S, St-Marie LG, Brown J, Evans AW, Rios L, Compston JE; Canadian Association of Oral and Maxillofacial Surgeons.

J Rheumatol. 2008 Jul;35(7):1391-7. Epub 2008 Jun 1. Erratum in: J Rheumatol. 2008 Oct;35(10):2084. J Rheumatol. 2008 Aug;35(8):1688.

PMID:
18528958
16.

Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis.

Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, Grbic J, Jontell M, Landesberg R, Laslop A, Wollenhaupt M, Papapoulos S, Sezer O, Sprafka M, Reginster JY.

Bone. 2008 May;42(5):841-7. doi: 10.1016/j.bone.2008.01.003. Epub 2008 Jan 18. Review.

PMID:
18314405
17.

Atypical fractures, a biased perspective.

Aspenberg P.

Injury. 2016 Jan;47 Suppl 1:S28-30. doi: 10.1016/S0020-1383(16)30007-9.

PMID:
26768286
18.

Long term bisphosphonate use in osteoporotic patients; a step forward, two steps back.

Salari P, Abdollahi M.

J Pharm Pharm Sci. 2012;15(2):305-17. Review.

19.

Bisphosphonates in the treatment of osteoporosis: a review of their contribution and controversies.

Reid IR.

Skeletal Radiol. 2011 Sep;40(9):1191-6. doi: 10.1007/s00256-011-1164-9. Epub 2011 Aug 17. Review.

PMID:
21847749
20.

Bisphosphonates in the treatment of osteoporosis.

Diab DL, Watts NB.

Endocrinol Metab Clin North Am. 2012 Sep;41(3):487-506. doi: 10.1016/j.ecl.2012.04.007. Epub 2012 Jun 9. Review.

PMID:
22877426

Supplemental Content

Support Center